Sca-1 is an early-response target of histone deacetylase inhibitors and marks hematopoietic cells with enhanced function

Experimental Hematology

Volumn 41, Issue 1, 2013, Pages

  Walasek, Marta A ^a   Bystrykh, Leonid V ^a   Olthof, Sandra ^a   de Haan, Gerald ^a   Van Os, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CELL MARKER; CELL PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN LIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL FUNCTION; CELL RENEWAL; CELL SURFACE; DRUG EXPOSURE; DRUG MECHANISM; EARLY RESPONSE GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GLUTATHIONE METABOLISM; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84870920015     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.09.004     Document Type: Article

References (47)

1. Akashi K., Traver D., Miyamoto T., Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000, 404:193-197.
2. Kondo M., Weissman I., Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997, 91:661-672.
3. Akashi K., He X., Chen J., et al. Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 2003, 101:383-389.
4. Passegue E., Jamieson C.H., Ailles L.E., Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc Natl Acad Sci U S A 2003, 100(suppl 1):11842-11849.
5. Adolfsson J., Månsson R., Buza-Vidas N., et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential: a revised road map for adult blood lineage commitment. Cell 2005, 121:295-306.
6. Månsson R., Hultquist A., Luc S., et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 2007, 26:407-419.
7. Kulessa H., Frampton J., Graf T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev 1995, 9:1250-1262.
8. Xie H., Ye M., Feng R., Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004, 117:663-676.
9. Laiosa C.V., Stadtfeld M., Xie H., de Andres-Aguayo L., Graf T. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBPα and PU.1 transcription factors. Immunity 2006, 25:731-744.
10. Challen G.A., Boles N., Lin K.K., Goodell M.A. Mouse hematopoietic stem cell identification and analysis. Cytometry Part A 2009, 75A:14-24.
11. de Bruijn M.F.T.R., Ma X., Robin C., Ottersbach K., Sanchez M., Dzierzak E. Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta. Immunity 2002, 16:673-683.
12. Holmes C., Stanford W.L. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007, 25:1339-1347.
13. Bradfute S.B., Graubert T.A., Goodell M.A. Roles of Sca-1 in hematopoietic stem/progenitor cell function. Exp Hematol 2005, 33:836-843.
14. Ma X., Robin C., Ottersbach K., Dzierzak E. The Ly-6A (Sca-1) GFP transgene is expressed in all adult mouse hematopoietic stem cells. Stem Cells 2002, 20:514-521.
15. Hanson P., Mathews V., Marrus S.H., Graubert T.A. Enhanced green fluorescent protein targeted to the Sca-1 (Ly-6A) locus in transgenic mice results in efficient marking of hematopoietic stem cells in vivo. Exp Hematol 2003, 31:159-167.
16. Uchida N., Weissman I.L. Searching for hematopoietic stem cells: evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J Exp Med 1992, 175:175-184.
17. Ito C.Y., Li C.Y., Bernstein A., Dick J.E., Stanford W.L. Hematopoietic stem cell and progenitor defects in Sca-1/Ly-6A-null mice. Blood 2003, 101:517-523.
18. Walasek M.A., Bystrykh L.V., van den Boom V., et al. The combination of valproic acid and lithium delays hematopoietic stem/progenitor cell differentiation. Blood 2012, 29(119):3050-3059.
19. Bug G., Gul H., Schwarz K., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65:2537-2541.
20. DeFelice L., Tatarelli C., Mascolo M.G., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005, 65:1505-1513.
21. Vulcano F., Milazzo L., Ciccarelli C., et al. Valproic acid affects the engraftment of TPO-expanded cord blood cells in NOD/SCID mice. Exp Cell Res 2012, 318:400-407.
22. Milhem M., Mahmud N., Lavelle D., et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004, 103:4102-4110.
23. Zini R., Norfo R., Ferrari F., et al. Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. Exp Hematol 2012 Aug 10, pii: S0301-472X(12)00344-X, [Epub ahead of print]. 10.1016/j.exphem.2012.08.003.
24. Chow A., Lucas D., Hidalgo A., et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011, 208:261-271.
25. Christopher M.J., Rao M., Liu F., Woloszynek J.R., Link D.C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011, 208:251-260.
26. Winkler I.G., Barbier V., Wadley R., Zannettino A.C., Williams S., Levesque J.P. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010, 116:375-385.
27. Altman D. Practical Statistics for Medical Research 1991, Chapman and Hall Books, London.
28. Pukelsheim F. The three sigma rule. Am Stat 1994, 48:88-91.
29. Backes C., Keller A., Kuentzer J., et al. GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Res 2007, 35:W186-W192.
30. van Os R.P., Dethmers-Ausema B., de Haan G. In vitro assays for cobblestone area-forming cells, LTC-IC, and CFU-C. Methods Mol Biol 2008, 430:143-157.
31. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp 1996, 5:243-253.
32. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003, 2:151-163.
33. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004, 101:540-545.
34. Min I.M., Pietramaggiori G., Kim F.S., Passegué E., Stevenson K.E., Wagers A.J. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2008, 2:380-391.
35. Tang W., Borel A.G., Abbott F.S. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases. Drug Metab Dispos 1996, 24:436-446.
36. Kiang T.K.L., Teng X.W., Surendradoss J., Karagiozov S., Abbott F.S., Chang T.K.H. Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity. Toxicol Appl Pharmacol 2011, 252:318-324.
37. Khan N., Jeffers M., Kumar S., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
38. Bug G., Schwarz K., Schoch C., et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92:542-545.
39. Leiva M., Moretti S., Soilihi H., et al. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 2012, 26:1630-1637.
40. Ungerstedt J.S., Sowa Y., Xu W.S., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102:673-678.
41. Huangfu D., Maehr R., Guo W., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008, 26:795-797.
42. Grafi G. The complexity of cellular dedifferentiation: implications for regenerative medicine. Trends Biotechnol 2009, 27:329-332.
43. Gaspar-Maia A., Alajem A., Meshorer E., Ramalho-Santos M. Open chromatin in pluripotency and reprogramming. Nat Rev Mol Cell Biol 2011, 12:36-47.
44. Kruger J.A., Kaplan C.D., Luo Y., et al. Characterization of stem cell-like cancer cells in immune-competent mice. Blood 2006, 108:3906-3912.
45. Mulholland D.J., Xin L., Morim A., Lawson D., Witte O., Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 2009, 69:8555-8562.
46. Essers M.A.G., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
47. van de Rijn M., Heimfeld S., Spangrude G.J., Weissman I.L. Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci 1989, 86:4634-4638.